GOLIM4

Across TCGA pan-cancer cohorts, GOLIM4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GOLIM4 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GOLIM4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLIM4 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

HNSC, COAD, and CCRCC are the cancer types where GOLIM4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.513	0.814	.003	67	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.910	.041	18	view →
CCRCC	OS	Median	All	0.714	1.000	.014	17	view →
LSCC	OS	Quartile	II,III,IV	0.737	1.000	.002	14	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GOLIM4–HNSC (DFS)

Open the HNSC breakdown →